Modulation of IL-33/ST2 system in postinfarction heart failure: Correlation with cardiac remodelling markers

European Journal of Clinical Investigation

Volumn 44, Issue 7, 2014, Pages 643-651

  Sánchez Más, Jesús ^a,b   Lax, Antonio ^a,b   Asensio López, María del Carmen ^a,b   Fernandez Del Palacio, Maria J ^c   Caballero, Luis ^a   Santarelli, Giorgia ^c   Januzzi, James L ^d   Pascual Figal, Domingo A ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Cardiac remodelling; Interleukin; ST2

Indexed keywords

CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; PROTEIN P53; ST2 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; INTERLEUKIN-33, RAT; MESSENGER RNA; ST2 PROTEIN, RAT;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDITIS; CONTROLLED STUDY; CORRELATIONAL STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SURGICAL MORTALITY; UPREGULATION; ANIMAL; CORONARY BLOOD VESSEL; FIBROSIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; LIGATION; METABOLISM; MYOCARDITIS; PATHOLOGY; PHYSIOLOGY; SURGERY; VASCULAR REMODELING; WISTAR RAT;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CORONARY VESSELS; FIBROSIS; HEART FAILURE; INTERLEUKINS; LIGATION; MALE; MYOCARDIAL INFARCTION; MYOCARDITIS; MYOCARDIUM; RATS, WISTAR; RECEPTORS, INTERLEUKIN-1; RNA, MESSENGER; UP-REGULATION; VASCULAR REMODELING;

EID: 84903373951     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12282     Document Type: Article

References (24)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB et al. Heart disease and stroke statistics 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245.
2. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 2009;81:482-90.
3. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-8.
4. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994;13:1176-88.
5. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-90.
6. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008;205:339-46.
7. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-49.
8. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009;2:684-91.
9. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-40.
10. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012;126:1596-604.
11. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-90.
12. Milo-Cotter O, Cotter-Davison B, Lombardi C, Sun H, Bettari L, Bugatti S et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology 2011;119:96-105.
13. Breidthardt T, Balmelli C, Twerenbold R, Mosimann T, Espinola J, Haaf P et al. Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance. J Card Fail 2013;19:821-8.
14. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-13.
15. Januzzi JL Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 2013;4:493-500.
16. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009;54:2174-9.
17. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-67.
18. Thomas WP, Gaber CE, Jacobs GJ, Kaplan PM, Lombard CW, Moise NS et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247-52.
19. Asensio-Lopez MC, Lax A, Pascual-Figal DA, Valdes M, Sanchez-Mas J. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic Biol Med 2011;51:1861-71.
20. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6.
21. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-44.
22. Abbate A, Bussani R, Amin MS, Vetrovec GW, Baldi A. Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol 2006;38:1834-40.
23. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL Jr. Soluble Concentrations of the Interleukin Receptor Family Member ST2 and Beta Blocker Therapy in Chronic Heart Failure. Circ Heart Fail 2013;6:1206-13.
24. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-50.